Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Case Report

Post Covid Juvenile Dermatomyositis with Non Hodgkins Lymphoma in a Child: A Case Report

Author(s): Neha Thakur*, Kiran Preet Malhotra and Pradyumun Singh

Volume 19, Issue 4, 2023

Published on: 03 May, 2023

Page: [504 - 507] Pages: 4

DOI: 10.2174/1573397119666230331083402

Price: $65

Abstract

Introduction: Juvenile dermatomyositis (JDM), a rare multisystemic autoimmune disease of unknown cause, leads to chronic inflammation of both striated and smooth muscles. SARS - Co V2 virus infection in children generally remain asymptomatic. However, in some children it leads to a detailed immunological response named as multisystem inflammatory syndrome in children (MIS-C). Post recovery, occasionally, children are susceptible to other autoimmune disorders.

Case Presentation: Our case post MIS-C developed JDM. 8-year-old malnourished child developed proximal myopathy of both upper and lower limbs post recovery from COVID 19. His disease severity increased within a short span of time and he went on to develop contractures and deformity of both upper and lower limbs. He developed an uncommon complication of JDM in form of highgrade non-Hodgkin’s lymphoma.

Conclusion: This case highlights the importance of long-term complications of COVID-19 in children which would gradually evolve in the next few years.

Graphical Abstract

[1]
Rider LG, Lindsley CB, Cassidy JT. Juvenile dermatomyositis, Textbook of paediatric rheum. (6th ed.). Saunders 2011; pp. 375-414.
[http://dx.doi.org/10.1016/B978-1-4160-6581-4.10024-X]
[2]
Meyer A, Meyer N, Schaeffer M, Gottenberg JE, Geny B, Sibilia J. Incidence and prevalence of inflammatory myopathies: A systematic review. Rheumatology 2015; 54(1): 50-63.
[http://dx.doi.org/10.1093/rheumatology/keu289]
[3]
Liquidano-Perez E, García-Romero MT, Yamazaki-Nakashimada M, et al. Juvenile dermatomyositis triggered by SARS-CoV-2. Pediatr Neurol 2021; 121: 26-7.
[http://dx.doi.org/10.1016/j.pediatrneurol.2021.05.011] [PMID: 34126319]
[4]
Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 european league against rheumatism/american college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017; 76(12): 1955-64.
[http://dx.doi.org/10.1136/annrheumdis-2017-211468] [PMID: 29079590]
[5]
Habibi S, Ramanan AV. Juvenile dermatomyositis: A review of clinical features and management. Indian J Rheumatol 2012; 7(1): 80-6.
[http://dx.doi.org/10.1016/S0973-3698(12)60032-6]
[6]
Cannon L, Dvergsten J, Stingl C. Juvenile dermatomyositis and development of malignancy: 2 case reports and a literature review. J Rheumatol 2020; 47(3): 479.
[http://dx.doi.org/10.3899/jrheum.190929] [PMID: 31941800]
[7]
Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020; 383(4): 334-46.
[http://dx.doi.org/10.1056/NEJMoa2021680] [PMID: 32598831]
[8]
Ramaswamy A, Brodsky NN, Sumida TS, et al. Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity 2021; 54(5): 1083-95.
[http://dx.doi.org/10.1016/j.immuni.2021.04.003] [PMID: 33891889]
[9]
Gara S, Jamil RT, Muse ME, et al. Juvenile Dermatomyositis. StatPearls. Treasure Island, FL: StatPearls Publishing 2021. Available From: https://www.ncbi.nlm.nih.gov/books/NBK534236

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy